Literature DB >> 16045746

FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease.

J Kelsen1, J Agnholt, H J Hoffmann, J L Rømer, C L Hvas, J F Dahlerup.   

Abstract

Summary CD4(+)CD25(+) regulatory T cells (T(regs)) are involved in the maintenance of peripheral tolerance and ensure a balanced immune response competent of fighting pathogens and at the same time recognizing commensals as harmless. This feature is lost in Crohn's disease (CD). The forkhead/winged helix transcription factor FoxP3 is a master gene for T(reg) function and defects in the FoxP3 gene lead to a clinical picture similar to inflammatory bowel disease (IBD). Murine colitis can be cured by adoptive transfer of T(regs) and ex vivo-generated gut-specific T(regs) represent an attractive option for therapy in CD. Thus, defective T(regs) could contribute to the development of CD. We cultured biopsies of colonic mucosa in the presence of high concentrations of interleukin (IL)-2 and IL-4 to overcome the anergic nature of naturally occurring CD4(+)CD25(+) T(regs) in the mucosa. We investigated the expression of FoxP3 and regulatory potential of gut-derived CD4(+)CD25(+) T cells cultured from patients with CD and healthy individuals. The FoxP3 expression was analysed by reverse transcriptase polymerase chain reaction (RT-PCR), and the suppressive effect of FoxP3(+)CD4(+)CD25(+) T cells on proliferation and cytokine production of autologous CD4(+) T cells was assessed by flow cytometry. Cultured gut-derived T cells with CD4(+)CD25(+) phenotype expressed FoxP3 and were able as the freshly isolated T(regs) from peripheral blood to suppress proliferation and cytokine production of autologous CD4(+) T cells. Thus, we demonstrate that FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be propagated in vitro from inflamed mucosa of CD patients, which may be of interest in adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16045746      PMCID: PMC1809448          DOI: 10.1111/j.1365-2249.2005.02876.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

Review 1.  Control of intestinal inflammation by regulatory T cells.

Authors:  B Singh; S Read; C Asseman; V Malmström; C Mottet; L A Stephens; R Stepankova; H Tlaskalova; F Powrie
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

2.  Human intestinal lamina propria and intraepithelial lymphocytes express receptors specific for chemokines induced by inflammation.

Authors:  W W Agace; A I Roberts; L Wu; C Greineder; E C Ebert; C M Parker
Journal:  Eur J Immunol       Date:  2000-03       Impact factor: 5.532

3.  Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells.

Authors:  H L Weiner
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

4.  Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease.

Authors:  J Agnholt; K Kaltoft
Journal:  Cytokine       Date:  2001-08-21       Impact factor: 3.861

5.  Human T regulatory cells can use the perforin pathway to cause autologous target cell death.

Authors:  William J Grossman; James W Verbsky; Winfried Barchet; Marco Colonna; John P Atkinson; Timothy J Ley
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

6.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)

Authors:  R Duchmann; I Kaiser; E Hermann; W Mayet; K Ewe; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

7.  Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood.

Authors:  H Jonuleit; E Schmitt; M Stassen; A Tuettenberg; J Knop; A H Enk
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

8.  Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.

Authors:  S Read; V Malmström; F Powrie
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

9.  Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.

Authors:  M K Levings; R Sangregorio; M G Roncarolo
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

Review 10.  Type 1 T regulatory cells.

Authors:  M G Roncarolo; R Bacchetta; C Bordignon; S Narula; M K Levings
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

View more
  25 in total

Review 1.  Epithelia: lymphocyte interactions in the gut.

Authors:  Stephanie Dahan; Franziska Roth-Walter; Paul Arnaboldi; Shradha Agarwal; Lloyd Mayer
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

2.  Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis.

Authors:  Emilio Cuadrado; Marta Alonso; Maria-Dolores de Juan; Pilar Echaniz; Juan-Ignacio Arenas
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

3.  Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.

Authors:  Ida Ricciardelli; Keith J Lindley; Marco Londei; Sonia Quaratino
Journal:  Immunology       Date:  2008-04-16       Impact factor: 7.397

4.  The Involvement of Immune Semaphorins in the Pathogenesis of Inflammatory Bowel Diseases (IBDs).

Authors:  Zahava Vadasz; Tova Rainis; Afif Nakhleh; Tharwat Haj; Jacob Bejar; Katty Halasz; Elias Toubi
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

Review 5.  Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Authors:  Christopher G Mayne; Calvin B Williams
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

6.  The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival.

Authors:  Meher K Rahman; Emilie H Midtling; Phyllis A Svingen; Yuning Xiong; Michael P Bell; Jeanne Tung; Tom Smyrk; Larry J Egan; William A Faubion
Journal:  J Immunol       Date:  2010-05-07       Impact factor: 5.422

7.  Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis.

Authors:  Holm H Uhlig; Janine Coombes; Christian Mottet; Ana Izcue; Claire Thompson; Andrea Fanger; Andrea Tannapfel; Jason D Fontenot; Fred Ramsdell; Fiona Powrie
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

8.  Quantitative in situ analysis of FoxP3+ T regulatory cells on transplant tissue using laser scanning cytometry.

Authors:  Hidenori Takahashi; Phillip Ruiz; Camillo Ricordi; Victor Delacruz; Atsushi Miki; Atsuyoshi Mita; Ryosuke Misawa; Scott Barker; George W Burke; Andreas G Tzakis; Hirohito Ichii
Journal:  Cell Transplant       Date:  2011-09-16       Impact factor: 4.064

9.  Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis.

Authors:  Vladislaw Muratov; Ann-Kristin Ulfgren; Marianne Engström; Kerstin Elvin; Ola Winqvist; Robert Löfberg; Joachim Lundahl
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

10.  Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells.

Authors:  P J Mannon; F Leon; I J Fuss; B A Walter; M Begnami; M Quezado; Z Yang; C Yi; C Groden; J Friend; R L Hornung; M Brown; S Gurprasad; B Kelsall; W Strober
Journal:  Clin Exp Immunol       Date:  2008-12-15       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.